Researchers identified demographic and socioeconomic factors associated with differences in staging of non-small cell lung cancer at initial presentation.
An analysis of published literature sought to measure the effects of social determinants of health on precision medicine for lung cancer in various racial and ethnic patient populations.
Medicaid beneficiaries had a higher risk of death than commercially-insured patients, but the risk of death decreased if Medicaid beneficiaries underwent biomarker testing.